Volume | 1 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vir Biotechnology Inc | VIR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.04 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 1 | - | 7.72 - 27.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:38:26 | 1 | $ 8.00 | USD |
Vir Biotechnology Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.09B | 135.03M | - | 86.18M | -615.06M | -4.55 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vir Biotechnology News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.21 | 8.40 | 7.755 | 8.03 | 954,391 | -0.17 | -2.07% |
1 Month | 10.16 | 10.34 | 7.755 | 8.92 | 829,286 | -2.12 | -20.87% |
3 Months | 9.44 | 12.00 | 7.755 | 10.00 | 1,031,760 | -1.40 | -14.83% |
6 Months | 8.35 | 12.00 | 7.72 | 9.69 | 1,128,455 | -0.31 | -3.71% |
1 Year | 25.27 | 27.48 | 7.72 | 12.82 | 1,181,074 | -17.23 | -68.18% |
3 Years | 49.39 | 58.00 | 7.72 | 25.08 | 1,147,354 | -41.35 | -83.72% |
5 Years | 16.15 | 141.01 | 7.72 | 30.76 | 1,133,516 | -8.11 | -50.22% |
Vir Biotechnology Description
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. |